DOI QR코드

DOI QR Code

Mutation Analysis of IDH1/2 Genes in Unselected De novo Acute Myeloid Leukaemia Patients in India - Identification of A Novel IDH2 Mutation

  • Raveendran, Sureshkumar (Division of Cancer Research, Regional Cancer Centre) ;
  • Sarojam, Santhi (Division of Cancer Research, Regional Cancer Centre) ;
  • Vijay, Sangeetha (Division of Cancer Research, Regional Cancer Centre) ;
  • Geetha, Aswathy Chandran (Division of Cancer Research, Regional Cancer Centre) ;
  • Sreedharan, Jayadevan (Gulf Medical University) ;
  • Narayanan, Geetha (Division of Medical Oncology, Regional Cancer Centre) ;
  • Sreedharan, Hariharan (Division of Cancer Research, Regional Cancer Centre)
  • Published : 2015.05.18

Abstract

IDH1/2 mutations which result in alternation in DNA methylation pattern are one of the most common methylation associated mutations in Acute myeloid leukaemia. IDH1/2 mutations frequently associated with higher platelet level, normal cytogentics and NPM1 mutations. Here we analyzed IDH1/2 mutations in 200 newly diagnosed unselected Indian adult AML patients and investigated their correlation with clinical, cytogenetic parameters along with cooperating NPM1 mutation. We detected 5.5% and 4% mutations in IDH1/2 genes, respectively. Except IDH2 c.515_516GG>AA mutation, all the other identified mutations were reported mutations. Similar to reported c.515G>A mutation, the novel c.515_516GG>AA mutation replaces $172^{nd}$ arginine to lysine in the active site of the enzyme. Even though there was a preponderance of IDH1/2 mutations in NK-AML, cytogenetically abnormal patients also harboured IDH1/2 mutations. IDH1 mutations showed significant higher platelet count and NPM1 mutations. IDH2 mutated patients displayed infrequent NPM1 mutations and lower WBC count. All the NPM1 mutations in the IDH1/2 mutated cases showed type A mutation. The present data suggest that IDH1/2 mutations are associated with normal cytogenetics and type A NPM1 mutations in adult Indian AML patients.

Keywords

Acute myeloid leukaemia;IDH1;IDH2;Type A NPM1 mutation

References

  1. Zhang Y, Wei H, Tang K,et al(2012). Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia. Genet Test Mol Biomarkers, 16, 991-5. https://doi.org/10.1089/gtmb.2011.0323
  2. Zhang Y, Wei H, Wang M, et al (2011). Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients. Leuk Res, 35, 1301-6. https://doi.org/10.1016/j.leukres.2011.01.019
  3. Zou Y, Zeng Y, Zhang DF, et al (2010). IDH1 and IDH2 mutations are frequent in Chinese patients with acute myeloid leukemia but rare in other types of hematological disorders. Biochem Biophys Res Commun, 402, 378-83. https://doi.org/10.1016/j.bbrc.2010.10.038
  4. Figueroa ME, Abdel-Wahab O, Lu C, et al (2010). Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell, 18, 553-67. https://doi.org/10.1016/j.ccr.2010.11.015
  5. Ghiam AF, Cairns RA, Thoms J, et al (2012). IDH mutation status in prostate cancer. Oncogene, 31, 3826. https://doi.org/10.1038/onc.2011.546
  6. Henegariu O, Heerema NA, Lowe Wright L, et al (2001). Improvements in cytogenetic slide preparation: Controlled chromosome spreading, chemical aging and gradual denaturing. Cytometry, 43, 101-9. https://doi.org/10.1002/1097-0320(20010201)43:2<101::AID-CYTO1024>3.0.CO;2-8
  7. Van den Bent MJ, Dubbink HJ, Marie Y, et al (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group. Clin Cancer Res, 16, 1597-604. https://doi.org/10.1158/1078-0432.CCR-09-2902
  8. Wagner K, Damm F, Gohring G, et al (2010). Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. J Clin Oncol, 28, 2356-64. https://doi.org/10.1200/JCO.2009.27.6899
  9. Ward PS, Patel J, Wise DR, et al (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell, 17, 225-34. https://doi.org/10.1016/j.ccr.2010.01.020
  10. Xu W, Yang H, Liu Y, et al (2011). Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of ${\alpha}$-ketoglutarate-dependent dioxygenases. Cancer Cell, 19, 17-30. https://doi.org/10.1016/j.ccr.2010.12.014
  11. Xu X, Zhao J, Xu Z,et al (2004). Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity. J Biol Chem, 279, 33946-57. https://doi.org/10.1074/jbc.M404298200
  12. Yamaguchi S, Iwanaga E, Tokunaga K, et al (2014). IDH1 and IDH2 mutations confer an adverse effect in patients with acute myeloid leukemia lacking the NPM1 mutation. Eur J Haematol, 92, 471-7. https://doi.org/10.1111/ejh.12271
  13. Cairns RA, Iqbal J, Lemonnier F, et al (2012). IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. Blood, 119, 1901-3. https://doi.org/10.1182/blood-2011-11-391748
  14. Chotirat S, Thongnoppakhun W, Promsuwicha O, et al (2012). Molecular alterations of Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients. J Hematol Oncol, 5, 1-10. https://doi.org/10.1186/1756-8722-5-1
  15. Chou WC, Hou HA, Chen CY, et al (2010). Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood, 115, 2749-54. https://doi.org/10.1182/blood-2009-11-253070
  16. Conway O'Brien E, Prideaux S, Chevassut T (2014). The epigenetic landscape of acute myeloid leukemia. Adv Hematol, 2014, 1-15.
  17. Dang L, Jin S, Su SM (2010). IDH mutations in glioma and acute myeloid leukemia. Trends Mol Med, 16, 387-397. https://doi.org/10.1016/j.molmed.2010.07.002
  18. Abbas S, Lugthart S, Kavelaars FG, et al (2010). Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood, 116, 2122-6. https://doi.org/10.1182/blood-2009-11-250878
  19. Ahmad F, Mohota R, Sanap S, et al (2014). Molecular evaluation of DNMT3A and IDH1/2 gene mutation: frequency, distribution pattern and associations with additional molecular markers in normal karyotype Indian acute myeloid leukemia patients. Asian Pac J Cancer Prev, 15, 1247-53. https://doi.org/10.7314/APJCP.2014.15.3.1247
  20. Dang L, White DW, Gross S, et al (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 462, 739-44. https://doi.org/10.1038/nature08617
  21. Dohner H, Gaidzik VI (2011). Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program, 2011, 36-42. https://doi.org/10.1182/asheducation-2011.1.36
  22. Patel KP, Ravandi F, Ma D, et al (2011). Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol, 135, 35-45. https://doi.org/10.1309/AJCPD7NR2RMNQDVF
  23. Patel JP, Gonen M, Figueroa ME, et al (2012). Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med, 366, 1079-89. https://doi.org/10.1056/NEJMoa1112304
  24. Patnaik MM, Hanson CA, Hodnefield JM, et al (2012). Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic study of 277 patients, Leukemia, 26, 101-5. https://doi.org/10.1038/leu.2011.298
  25. Schnittger S, Haferlach C, Ulke M, et al (2010). IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood, 116, 5486-96. https://doi.org/10.1182/blood-2010-02-267955
  26. Shaffer LG, McGowan-Jordan J, Schmid M (eds). ISCN 2013: An International System for Human Cytogenetic Nomenclature (2013). Basel, Karger, 2013.
  27. Shih AH, Abdel-Wahab O, Patel JP,et al(2012). The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer, 12, 599-612. https://doi.org/10.1038/nrc3343
  28. Ahmad F, Mandava S, Das BR (2009). Mutations of NPM1 gene in de novo acute myeloid leukaemia: determination of incidence, distribution pattern and identification of two novel mutations in Indian population. Hematol Oncol, 27, 90-7. https://doi.org/10.1002/hon.883
  29. Amary MF, Bacsi K, Maggiani F, et al (2011). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours. J Pathol, 224, 334-43. https://doi.org/10.1002/path.2913
  30. Borger DR, Tanabe KK, Fan KC, et al (2012). Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist, 17, 72-9. https://doi.org/10.1634/theoncologist.2011-0386
  31. Ley TJ, Miller C, Ding L, et al (2013). Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med, 368, 2059-74. https://doi.org/10.1056/NEJMoa1301689
  32. Lin J, Qian J, Yao DM, et al (2011). Rapid and reliable detection of IDH1 R132 mutations in acute myeloid leukemia using high-resolution melting curve analysis. Clin Biochem, 44, 779-83. https://doi.org/10.1016/j.clinbiochem.2011.04.014
  33. Losman JA, Kaelin WG Jr (2013). What a difference a hydroxyl makes:mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev, 27, 836-52. https://doi.org/10.1101/gad.217406.113
  34. Marcuccii G, Maharry K, Wu YZ, et al (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol, 28, 2348-55. https://doi.org/10.1200/JCO.2009.27.3730
  35. Mardis ER, Ding L, Dooling DJ, et al (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med, 361, 1058-66. https://doi.org/10.1056/NEJMoa0903840
  36. Ho PA, Kopecky KJ, Alonzo TA, et al (2011). Prognostic implications of the IDH1 synonymous SNP rs11554137 in pediatric and adult AML: a report from the children's oncology group and SWOG. Blood, 118, 4561-6. https://doi.org/10.1182/blood-2011-04-348888
  37. Im AP, Sehgal AR, Carroll MP, et al (2014). DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies. Leukemia, 28, 1774-83. https://doi.org/10.1038/leu.2014.124
  38. Parsons DW, Jones S, Zhang X, et al (2008). An integrated genomic analysis of human glioblastoma multiforme. Science, 321, 1807-12. https://doi.org/10.1126/science.1164382
  39. Paschka P, Schlenk RF, Gaidzik VI, et al (2010). IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol, 28, 3636-43. https://doi.org/10.1200/JCO.2010.28.3762